Eales' disease: Oxidant stress and weak antioxidant defence

Indian Journal of Ophthalmology

Volumn 55, Issue 2, 2007, Pages 95-102

  Ramakrishnan, S ^a   Rajesh, M ^a   Sulochana, K ^a  

^a VISION RESEARCH FOUNDATION   (India)

Author keywords

Beneficial therapy; Decreased antioxidant defence; Eales' disease; Increased oxidant stress

Indexed keywords

EID: 33947106942     PISSN: 03014738     EISSN: 03014738     Source Type: Journal    
DOI: 10.4103/0301-4738.30701     Document Type: Review

References (52)

1. Eales H. Retinal hemorrhages associated with epistaxis and constipation. Brim Med Rev 1880;9:262-73.
2. Eales H. Primary retinal hemorrhage in young men. Ophthalmic Rev 1882;1:41-6.
3. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales' Disease-an update. Surv Ophthalmol 2002;47:197-214.
4. Sulochana KN, Rajesh M, Ramakrishnan S. Purification and characterization of an 88 kDa novel protein from patients with Eales disease. Exp Eye Res 2001;73:547-55.
5. Bhooma V, Sulochana KN, Biswas J, Ramakrishnan S. Eales' disease: Accumulation of reactive oxygen intermediates and lipid peroxides and decrease of antioxidants causing inflammation, neovascularization and retinal damage. Curr Eye Res 1997;16:91-5.
6. Roth DB. Eales Disease. eMed J 2001;2:2-11.
7. Biswas J, Sulochana KN, Ramakrishnan S, Madhavan HN. Eales' disease-Clinical and basic research at Sankara Nethralaya. Uveitis Today: Elsevier Science; 1998. p. 111-4.
8. Das T, Biswas J, Kumar A, Nagapal PN, Namperumalswamy P, Patnaik B et al. Eales' disease. Indian J Ophthalmol 1994;42:3-18.
9. Charmis J. On the classification and management of the evolutionary course of Eales' disease. Trans Ophthalmol Soc UK 1965;85:157-60.
10. Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol 2004;14:236-9.
11. Biswas J, Badrinath SS. Ocular morbidity in patients with active systemic tuberculosis. Int Opthalmol 1995;19:293-8.
12. Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of Mycobacterium tuberculosis complex DNA from vitreous sample of Eales' disease. Br J Ophthalmol 1999;83:994.
13. Madhavan HN, Therese L, Gurisha P, Jayanthi U, Biswas J. Polymerase chain reaction in detection of Mycobacterium tuberculosis complex DNA from vitreous sample of Eales disease. Invest Opthalmol Vis Sci 2000;41:882.
14. Badrinath SS, Biswas J, Sharma. Immunophenotyping of inflammatory infiltrates in epiretinal (ERM) and subretinal membrane (SRM) in Eales disease. Invest Opthalmol Vis Sci 1992;88:857.
15. Biswas J, Rao NA. Epiretinal membrane in Eales disease and other vacular retinopathies. Invest Opthalmol Vis Sci 2001;31:369.
16. Saxena S, Rajasingh J, Biswas S, Kumar D, Shinohara T, Singh VK. Cellular immune response to retinal S-antigen and interphotoreceptor retinoid-binding protein fragments in Eales' disease patients. Pathobiology 1999;67:39-44.
17. Pratap VB, Mehra MK, Gupta RK. Electrophoretic pattern of serum proteins in Eales' disease. Indian J Ophthalmol 1976;23:14-6.
18. Rengarajan K, Muthukkaruppan VR, Namperumalswamy P. Biochemical analysis of serum proteins from Eales' patients. Curr Eye Res 1989;8:1259-69.
19. Sen DK, Sarin GS, Ghosh B, Acharya NR, Gurha N. Serum alpha-1-acid glycoprotein levels in patients with idiopathic peripheral retinal periphlebitis. Acta Ophthalmol (Copenh) 1992;70:515-7.
20. Rao NA, Thaete LG, Delmage JM, Sevanian A. Superoxide dismutase in ocular structures. Invest Ophthalmol Vis Sci 1985;26:1778-81.
21. Armstrong D, Hartnett M, Browne R Ueda T, Jenis E, Aljada A, et al. Lipid peroxide-induced synthesis of cytokine growth factors during neovascularization in retina. Ind J Biochem Biophy 1995;36:455.
22. Selvi R, Ramakrishnan S, Angayarkanni N. Homocysteinylation of Plasma proteins in hyperhomocyteinemia cases of Eales' disease - a retinal vascular disease. Annual Meeting of Society of Biological Chemists (India). Lucknow; 2005. p. 33.
23. Wilcken DE, Gupta VJ. Cysteine-homocysteine mixed disulphide: Differing plasma concentrations in normal men and women. Clin Sci 1979;57:211-5.
24. Andersson A, Brattstrom L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender and menopausal status. Eur J Clin Invest 1992;22;79-97.
25. Ueland PM, Refsum H. Plasma homocysteine and cardiovascular diseases. Fundament Clin Cardiol 1992;8:83.
26. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000;355:523-7.
27. Sulochana KN, Biswas J, Ramakrishnan, S. Eales' disease: Increased oxidation and peroxidation products of membrane constituents chiefly lipids and decreased antioxident enzymes and reduced glutathione in vitreous. Curr Eye Res 1999;19:254-9.
28. Swamy-Mruthinti S, Miriam KC, Kumar SK, Biswas J, Ramakrishnan S, Nagaraj RH, et al. Immunolocalization and quantification of advanced glycation end products in retinal neovascular membranes and serum: A possible role in ocular neovascularization. Curr Eye Res 2002;25:139-45.
29. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101:1219-24.
30. Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723-30.
31. Rajesh M, Sulochana KN, Ramakrishnan S, Biswas J, Manoharan PT. Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients' with Eales' disease: Direct evidence using electron spin resonance spectroscopy. Curr Eye Res 2004;28:399-407.
32. Rajesh M, Ramesh A, Ravi PE, Balakrishnamurthy P, Coral K, Punitham R, et al. Accumulation of 8 hydroxydeoxyguanosine and its relationship with antioxidant parameters in patients with Eales' disease: Implications for antioxidant therapy. Curr Eye Res 2003;27:103-10.
33. Rajesh M, Sulochana KN, Punitham R, Biswas J, Lakshmi S, Ramakrishnan S. Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales' disease. Clin Biochem 2003;36:377-85.
34. Fischer PA, Dominguez GN, Cuniberti LA, Martinez V, Werba JP, Ramirez AJ, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: Is nitric oxide involved? J Am Soc Nephrol 2003;14:653-60.
35. Er H, Evereklioglu C, Cumurcu T, Türköz Y, Özerol E, Sahin K, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002;86:653-7.
36. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. Surv Ophthalmol 1997;42:71-82.
37. Saxena S, Khanna VK, Kumar D, Srivastava P, Seth PK. Enhanced oxidative stress in Eales' disease. Ann Ophthalmol 2001;33:40-2.
38. Saxena S, Kumar D, Srivastava P, Khanna VK, Seth PK. Low levels of platelet glutathione in Eales' disease. Low levels of platelet glutathione in Eales' disease. Med Sci Res 1999;42:125-6.
39. Saxena S, Khanna VK, Srivastava P, Kumar D, Seth PK. Decreased platelet membrane fluidity in retinal periphlebitis in Eales' disease. Ocul Immunol Inflamm 2006;14:113-6.
40. Srivatsava P, Saxena S, Khanna KV, Kumar D, Nath R, Seth KP. Raised platelet thiobarbituric acid reacting substances in proliferative Eales' disease. Indian J Ophthalmol 2000;48:307-9.
41. Saxena S, Kumar VK, Srivastava P, Seth PK. Impaired antioxidant defence mechanism in central Eales' disease. Ann Ophthalmol 2004;30:29-31.
42. Ramakrishnan S. A Novel 88 kDa acute phase protein in inflammation and its antioxidant function. Focus on Eye Research. Nova Science Publishers Inc: NY; 2005.
43. Bali T, Saxena S, Kumar D, Nath R. Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis. Eur J Opthalmol 2005;15:374-8.
44. Saxena S, Kumar D, Tiwari T, Bhasker SK, Srivastava P, Khanna VK, et al. Ind Eye Res Group 2003;Abst. 25.
45. Ramakrishnan S, Sulochana KN. Antioxidant vitamins E, C and A. Insight 1999; 59-60.
46. Rooij JV, Schwartzenberg SG, Mulder PG, Baarsme SG. Oral vitamin C and E as adult treatment in patients with acute anterior uveitis: A randomized double masked study in 145 patients. Br J Ophthalmol 1999;83:1277-82.
47. rd ed. M/S Orient Longman Ltd: Chennai; 2002. p. 392-9.
48. FACT Book-Vitamin E. Gallup Survey of vitamin usage in the United States. 1993;17:26-27.
49. Recent trends in antioxidant vitamin therapy, Vitamin C, antioxidant action. Cadilla Pharmaceuticals Ltd: Ahmedabad; 1997. p. 6.
50. Hand book on "Racing Towards 2000. Oxyace JB. Chemicals and Pharmaceuticals Ltd: Mumbai; 1995;25:p. 12.
51. Ramakrishnan S, Sulochana KN, Lakshmi S, Selvi R, Angayarkanni N. Biochemistry of homocysteine in health and diseases. Indian J Biochem Biophys 2006;43:275-83.
52. Durand P, Prost M, Loreau N, Lussier-Cacan S, Blache D. Impaired Homocysteine metabolism and atherothrombotic disease. Lab Invest 2001;81:645-72.